Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed FCF Margin for 9 consecutive years, with 499.11% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 48124.0% to 499.11% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 121.87% through Dec 2025, up 7924.0% year-over-year, with the annual reading at 121.87% for FY2025, 7980.0% up from the prior year.
  • FCF Margin hit 499.11% in Q4 2025 for Protagonist Therapeutics, down from 69.61% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 6440.89% in Q2 2024 to a low of 1502.44% in Q2 2022.
  • Historically, FCF Margin has averaged 95.05% across 5 years, with a median of 213.35% in 2021.
  • Biggest five-year swings in FCF Margin: plummeted -1141244bps in 2021 and later soared 54286bps in 2025.
  • Year by year, FCF Margin stood at 314.9% in 2021, then surged by 91bps to 28.77% in 2022, then skyrocketed by 689bps to 169.41% in 2023, then tumbled by -111bps to 17.87% in 2024, then tumbled by -2693bps to 499.11% in 2025.
  • Business Quant data shows FCF Margin for PTGX at 499.11% in Q4 2025, 69.61% in Q3 2025, and 510.96% in Q2 2025.